Organisation paid for research Program year 2025 Source: CMS Open Payments

Optimus U Corp

Neither a doctor nor a teaching hospital

Research payments

$29,021,323

525 payments

Through program year 2025, Optimus U Corp is reported as receiving $29,021,323 in research payments, across 525 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$4,496,081	87
2024	Research	$5,553,314	40
2023	Research	$4,275,729	92
2022	Research	$7,767,685	122
2021	Research	$3,223,525	69
2020	Research	$2,059,612	41
2019	Research	$1,645,377	74

Breakdown

Who paid Research payments · program years 2019–2025

Pfizer Inc. $10,401,616 210 payments
Genentech, Inc. $6,105,446 67 payments
Bavarian Nordic A/S $3,752,276 50 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $2,311,902 29 payments
Alnylam Pharmaceuticals Inc. $1,985,881 40 payments
Roche Diagnostics Operations, Inc. $1,529,051 22 payments
AbbVie, Inc. $1,236,691 31 payments
Ironwood Pharmaceuticals, Inc $595,626 17 payments
GlaxoSmithKline, LLC. $471,962 11 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $399,400 7 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $6,925,627 39 payments
Gantenerumab in Early Ad $3,424,438 42 payments
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age $2,019,210 39 payments
Nct05238025 $1,733,067 11 payments
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $1,543,715 14 payments
Rd006263 $1,529,051 22 payments
A Phase 12 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza in Healthy Individuals $1,503,277 32 payments
Prevention Study $1,355,194 8 payments
A Phase 2 Randomized Doubleblind Doubledummy Placebocontrolled Doseranging Dosefinding Parallel Group Study to Assess Efficacy and Safety of Pf06865571 Dgat2i Alone and When Coadministered With Pf05221304 Acci in Adult Participants With Biopsyconfirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 Or 3 $1,119,575 51 payments
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) $1,001,803 26 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.